Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 1999

View Archived Issues

Genzyme General's Seprafilm approved in Europe for cardiac surgery

Growth factors shown to improve muscle healing in animal models

Merck terminates negotiations with Bioject

Biogen and Ontogeny extend hedgehog protein collaboration

Magainin reports interim results of squalamine trial

Two German pharmaceutical companies join forces in urology segment

Millennium Preventive Medicine and Becton Dickinson establish diagnostics alliance

Aurora enters screening agreement with Roche

Novel BK channel modulators developed at Bristol-Myers Squibb

Azacycloalkane derivatives for diabetes and related disorders patented by Synthelabo

Fujisawa's new hypoglycemic and hypolipidemic agents

CNS compounds from Merck acting on serotonergic system

Bayer claims oxazolidinones active against Gram-positive bacteria and mycobacteria

Clinically effective antiarthritic drug offered for licensing by KS Biomedix

Company Profile: Almirall Prodesfarma

New Vasogen technology protects against GVHD in animal model

C5a receptor antagonist with therapeutic potential in endotoxic shock, ARDS

Cubist reports new developments in antibiotic program

Eradication of H. pylori may prevent long-term NSAID-related ulcers

Nevirapine-containing triple combination therapy effective in advanced HIV disease or AIDS

Cortecs concludes phase III Macritonin trial

Matrix begins treating patients in phase II study of FMdC

Muse granted marketing approval in Germany

Rofecoxib up for advisory committee review this spring

InKine schedules pre-NDA meeting with FDA for INKP-100

Zimmer launches Orthovisc in Europe; prepares to begin North American trials

Worldwide strategic alliance established by Agennix and Santen for lactoferrin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...